TY - JOUR
TI - MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma
AU - Nofech-Mozes, R.
AU - Khella, H.W.Z.
AU - Scorilas, A.
AU - Youssef, L.
AU - Krylov, S.N.
AU - Lianidou, E.
AU - Sidiropoulos, K.G.
AU - Gabril, M.
AU - Evans, A.
AU - Yousef, G.M.
JO - Cancer Medicine
PY - 2016
VL - 5
TODO - 4
SP - 656-664
PB - Wiley-Blackwell Publishing Ltd
SN - 2045-7634
TODO - 10.1002/cam4.631
TODO - microRNA;  microRNA 194;  unclassified drug;  microRNA;  MIRN194 microRNA, human;  tumor marker, adult;  Article;  BCL2 gene;  cancer classification;  cancer growth;  cancer prognosis;  cancer staging;  carcinogenesis;  cohort analysis;  computer model;  controlled study;  CRK gene;  disease free survival;  down regulation;  female;  gene;  HIF1A gene;  histopathology;  human;  human tissue;  IGF1R gene;  ITGB1 gene;  kidney;  kidney carcinoma;  kidney tumor;  major clinical study;  male;  MAPK gene;  MAPK1 gene;  MDM2 gene;  metastasis potential;  mTOR gene;  oncocytoma;  overall survival;  PIK3R2 gene;  prediction;  priority journal;  protein expression;  signal transduction;  TGF beta gene;  tumor volume;  VEGF gene;  Wnt gene;  aged;  biology;  cancer grading;  disease course;  gene expression regulation;  genetic database;  genetics;  Kaplan Meier method;  kidney carcinoma;  kidney tumor;  metastasis;  middle aged;  mortality;  pathology;  procedures;  prognosis, Adult;  Aged;  Biomarkers, Tumor;  Carcinoma, Renal Cell;  Computational Biology;  Databases, Genetic;  Disease Progression;  Female;  Gene Expression Regulation, Neoplastic;  Humans;  Kaplan-Meier Estimate;  Kidney Neoplasms;  Male;  MicroRNAs;  Middle Aged;  Neoplasm Grading;  Neoplasm Metastasis;  Neoplasm Staging;  Prognosis
TODO - Clear cell renal cell carcinoma (ccRCC) is the most prevalent adult kidney cancer. Prognostic markers are needed to guide patient management toward aggressive versus more conservative approaches, especially for small tumors ≤4 cm. miR-194 was reported to be downregulated in several cancers and is involved in epithelial to mesenchymal transition. We evaluated miR-194 as a prognostic marker in ccRCC. In a cohort of 234 patients with primary ccRCC, we correlated miR-194 expression level with multiple clinicopathological features including disease-free and overall survival, tumor size, clinical stage, and histological grade. Our results shows a stepwise decrease in miR-194 expression from normal kidney to primary ccRCC (P = 0.0032) and a subsequent decrease from primary to metastatic lesions. Additionally, patients with higher miR-194 expression has significantly longer disease-free survival (P = 0.041) and overall survival (P = 0.031) compared to those with lower expression. In multivariate analysis, miR-194-positive tumors retain significance in disease-free survival and overall survival, suggesting miR-194 is an independent marker for good prognosis in ccRCC. Moreover, miR-194 is a marker for good prognosis for patients with small renal masses (P = 0.014). These findings were validated on an independent data set from The Cancer Genome Atlas. We also compared miR-194 expression between RCC subtypes. ccRCC had the highest levels, whereas chromophobe RCC and oncocytoma had comparable lower levels. Target prediction coupled with pathway analysis show that miR-194 is predicted to target key molecules and pathways involved in RCC progression. miR-194 represents a prognostic biomarker in ccRCC. © 2016 Published by John Wiley & Sons Ltd.
ER -